Wednesday, January 25, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

BARDA Seeks Input from Suppliers on Potential SARS-CoV-2 Medical Countermeasures

by Global Biodefense Staff
February 2, 2020
BARDA Seeks Input from Suppliers on Potential SARS-CoV-2 Medical Countermeasures

To support U.S. government medical countermeasure research and development in response to the COVID-19 outbreak, the Biomedical Advanced Research Development Authority (BARDA) is providing a portal to simplify submission of market research packages from interested stakeholders.

The U.S. government, in response to the 2019 novel coronavirus outbreak, seeks information from stakeholders on available medical countermeasures in development. BARDA is particularly interested in products and technologies that have progressed into or beyond non-clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform. Information regarding diagnostics, therapeutics, vaccines, and other products or technologies relevant to addressing this outbreak are sought.

Ideal technologies and products will be:

  • Relevant to the U.S. government nCoV medical countermeasure research and development efforts and/or the BARDA Emerging Infectious Disease mission
  • Utilize an already-approved platform, have non-clinical data suggesting efficacy, and/or have significant manufacturing capability
  • Fully owned or licensed by your organization (you have full IP rights)

Submit your market research package: 2019 nCoV Market Research Submission Form.

Submissions will be accepted for an indeterminate period of time.

This article was updated on Feb 11 to reflect the naming of the virus from the provisional 2019-nCoV to SARS-CoV-2. The disease caused by SARS-CoV-2 is now called COVID-19.


Related Reading from Global Biodefense:

  • 51 FDA Approved Medical Countermeasures Backed by BARDA
  • Inflammatix Wins BARDA Backing for Diagnostic to Rapidly Distinguish Bacterial from Viral Infections
  • Project BioShield: Building a Better Medical Countermeasure Pipeline
  • BARDA Extends Strategic Partnership with JLABS
  • BARDA Backs Antibody Therapy Against MERS Virus
  • MERS-CoV: Clinical Trial Starts for Regeneron’s Monoclonal Antibody Treatments
  • Detecting Infection Before Symptoms Occur by Monitoring the Vagus Nerve
Tags: AntiviralsASPRBARDACoronavirusCOVID-19Drug DevelopmentEditor PickHHSMagazine Edition 6 Feb 2020Rapid DiagnosticsRFIVaccines

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC